Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer

Model scores of the 29,894 trials active now.

Model score 12% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 1.6% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerdlstagecelldefined
  Phrases that lowered it: patients whobevacizumabepithelialhave receivedovarian
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Collaborators: 3 (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports with a death: 33.7% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 62 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports marked serious: 96.5% (raises risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 75 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Neoadjuvant Therapy for Ovarian Cancer NCT01146795 · started 2010 · scored riskier than 48% of active trials completed
• First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer NCT01097746 · started 2010 · scored riskier than 72% of active trials completed
• Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer NCT02121990 · started 2014 · scored riskier than 15% of active trials completed
• Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma NCT00868192 · started 2008 · scored riskier than 49% of active trials completed
• Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT00951496 · started 2009 · scored riskier than 18% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.